von Willebrand Disease Profile, Plasma
Use
The von Willebrand Disease Profile is used for the detection of deficiency or abnormality in von Willebrand factor (VWF) and the related deficiency of factor VIII coagulant activity. It helps in subtyping von Willebrand disease (VWD) as type 1 (most common), type 2 variants (less common), or type 3 (rare). The test is critical for diagnosing the most common inherited bleeding disorder, affecting up to 1% of the population.
Special Instructions
Not provided.
Limitations
The VWF activity assay is not useful for differentiating between type 2A and 2B VWD or platelet-type VWD. The test should be done prior to any transfusion, VWF replacement therapy, and when the patient is free from such treatments. Mild type 1 VWD and borderline levels require careful interpretation with clinical correlation.
New York Approved
Methodology
Immunoassay (Latex Immunoassay (LIA))
Biomarkers
LOINC Codes
- 48593-8 - von Willebrand Pnl PPP
- 3209-4 - Fact VIII Act/Nor PPP
- 27816-8 - vWF Ag Act/Nor PPP IA
- 48595-3 - von Willebrand eval PPP-Imp
- 68324-3 - vWf:Ac Act/Nor PPP IA
Result Turnaround Time
2-12 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL in 3 plastic vials, each containing 1 mL
Minimum Volume
2 Plastic vials, each containing 1 mL
Container
Light-blue top (3.2% sodium citrate)
Collection Instructions
Specimen must be collected prior to factor replacement therapy. Centrifuge, transfer plasma into a plastic vial, and centrifuge plasma again. Aliquot plasma into 3 separate vials and freeze immediately at -20°C or -40°C.
Patient Preparation
Patient should not be on anticoagulant treatment. It is best to perform this study pretransfusion or wait 48 hours post-transfusion.
Storage Instructions
Freeze plasma immediately at -20°C or ideally at -40°C or below.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |